Pemafibrate Increases Circulating Angiopoietin-like Proteins 3 and 4 Without Promoting Pro-Atherogenic Changes in LDL and HDL Subspecies: A Post-Hoc Analysis of the PRESTIGE Study
Pemafibrate markedly elevated circulating ANGPTL3 and ANGPTL4 levels, but these increases were not associated with pro-atherogenic changes in lipoprotein profiles. Notably, baseline ANGPTL3 concentrations may influence the effect of fibrates on LDL-C levels.
Authors
- Yasuki Ito (ORCID: https://orcid.org/0000-0001-9219-9261)
- Atsuko Tamasawa
- Michishige Terasaki (ORCID: https://orcid.org/0000-0002-7405-7419)
- Makoto Ohara (ORCID: https://orcid.org/0000-0002-6137-5493)
- Yusaku Mori (ORCID: https://orcid.org/0000-0002-1734-0605)
- Tsutomu Hirano (ORCID: https://orcid.org/0000-0003-1859-0005)
- Toshiyuki Hayashi
- Sho-ichi Yamagishi
- Hiroe Sugita
Institutions
- SHOWA Medical University (JP)
- Diabetes Australia (AU)
- Taoka Hospital (JP)
- Osaka Nishi Clinic (JP)
- Ebina General Hospital (JP)
- CS Diagnostics (DE)
Publication Details
- Journal
- Journal of Atherosclerosis and Thrombosis
- Published
- 2025-10-03
- DOI
- https://doi.org/10.5551/jat.65941
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kowa Company